Insider Selling: Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CFO Sells 4,028 Shares of Stock

Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) CFO Blaine Davis sold 4,028 shares of the business's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $16.83, for a total value of $67,791.24. Following the completion of the transaction, the chief financial officer now directly owns 94,811 shares in the company, valued at $1,595,669.13. This represents a 4.08 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Blaine Davis also recently made the following trade(s):

• On Friday, January 3rd, Blaine Davis sold 3,961 shares of Cartesian Therapeutics stock. The shares were sold at an average price of $16.72, for a total value of $66,227.92.

Cartesian Therapeutics Stock Down 2.7 %

RNAC traded down $0.47 during mid-day trading on Tuesday, reaching $17.16. 105,686 shares of the company traded hands, compared to its average volume of 132,021. The stock has a market capitalization of $436.12 million, a P/E ratio of -0.32 and a beta of 0.56. Cartesian Therapeutics, Inc. has a 52-week low of $11.66 and a 52-week high of $41.87. The company's fifty day moving average price is $19.32 and its 200-day moving average price is $18.19.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on RNAC. Cantor Fitzgerald upgraded Cartesian Therapeutics to a "hold" rating in a report on Monday, December 2nd. BTIG Research initiated coverage on Cartesian Therapeutics in a research report on Thursday, December 19th. They set a "buy" rating and a $42.00 price target on the stock. Needham & Company LLC restated a "buy" rating and issued a $41.00 target price on shares of Cartesian Therapeutics in a research note on Tuesday, December 3rd. Finally, HC Wainwright reaffirmed a "buy" rating and set a $45.00 price objective (up from $41.00) on shares of Cartesian Therapeutics in a report on Wednesday, December 4th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $42.86.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in RNAC. BNP Paribas Financial Markets grew its stake in Cartesian Therapeutics by 122.5% during the third quarter. BNP Paribas Financial Markets now owns 1,651 shares of the company's stock valued at $27,000 after acquiring an additional 909 shares in the last quarter. Point72 DIFC Ltd purchased a new position in shares of Cartesian Therapeutics in the 2nd quarter worth approximately $47,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Cartesian Therapeutics during the second quarter valued at $49,000. Barclays PLC raised its position in Cartesian Therapeutics by 208.6% in the 3rd quarter. Barclays PLC now owns 11,611 shares of the company's stock worth $188,000 after purchasing an additional 7,849 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in Cartesian Therapeutics during the 2nd quarter valued at $351,000. 86.95% of the stock is owned by hedge funds and other institutional investors.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.